IP Library Granted Patent US 11,390,627
Granted Patent B2
US 11,390,627 · App. 17/014,134 · Granted Jul 19, 2022

Process for improved opioid synthesis

Inventors: Stuart James Gebbie (Norwood, MA); Joshua R. Giguere (Sharon, MA); Keith Mccarthy (Old Lyme, CT); Lonn S. Rider (Foster, RI)
Assignee: RHODES TECHNOLOGIES
C07D489/08Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,390,627
App. No.
17/014,134
Granted
Jul 19, 2022
Kind
B2
Abstract

Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.

Claims (17)

1. A compound, which is a hydrate of an isolated sulfate compound having the formula:

wherein:

R 2 is —H, —CH 3 , —(C 2 -C 7 )alkyl, —(C 2 -C 4 )alkenyl, benzyl, —(C 1 -C 7 )alkyl-(C 3 -C 7 )cycloalkyl, —CN, or an N-protecting group.

2. A composition, comprising the compound of claim 1 .

3. The compound of claim 1 , wherein the hydrate is a hydrate containing from 0.5 to 10.0 water molecules per molecule of the isolated sulfate compound.

4. The compound of claim 1 , wherein the hydrate is a monohydrate, dihydrate, trihydrate, tetrahydrate, pentahydrate, or hexahydrate.

5. The compound of claim 4 , wherein the hydrate is a monohydrate or dihydrate.

6. The compound of claim 1 , which is a hydrate of a compound having the formula:

wherein R 2 is as defined in claim 1 .

7. The compound of claim 1 , wherein R 2 is H or CH 3 .

8. The compound of claim 1 , wherein R 2 is —(C 2 -C 7 )alkyl, —(C 2 -C 4 )alkenyl, benzyl, —(C 1 -C 7 )alkyl-(C 3 -C 7 )cycloalkyl, —CN, or an N-protecting group.

9. The composition of claim 2 , further comprising a compound of formula III:

wherein R 1 is —CH 3 ; and

R 2 is —H, —CH 3 , —(C 2 -C 7 )alkyl, —(C 2 -C 4 )alkenyl, benzyl, —(C 1 -C 7 )alkyl-(C 3 -C 7 )cycloalkyl, —CN, or an N-protecting group, or a salt or hydrate thereof.

10. The composition of claim 9 , wherein the composition comprises the compound of formula III, or a salt or solvate thereof, in an amount of less than about 1500 ppm, of the sulfate compound (HPLC peak area ratio).

11. The composition of claim 9 , wherein the composition comprises the compound of formula III, or a salt or solvate thereof, in amount of less than about 500 ppm of the sulfate compound (HPLC peak area ratio).

12. The composition of claim 9 , wherein the composition comprises the compound of formula III, or a salt or solvate thereof, in an amount of less than about 100 ppm of the sulfate compound (HPLC peak area ratio).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2026
From: RHODES TECHNOLOGIES
To: KNOA PHARMA LLC
Reel/Frame 075838/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2022
From: GEBBIE, STUART JAMES; GIGUERE, JOSHUA R.; MCCARTHY, KEITH; RIDER, LONN S.
To: RHODES TECHNOLOGIES
Reel/Frame 058987/0807 →
Continuity (6)
Continuation 16270969 · Feb 8, 2019
Continuation 15700345 · Sep 11, 2017
Division 14413360
Provisional Application 61762657 · Feb 8, 2013
Provisional Application 61672265 · Jul 16, 2012
Related Publication 20210094964A1 · Apr 1, 2021